Testing a new eye drop for corneal scars
Part of Brain & nervous system, Eyes & vision, Injuries & trauma clinical trials.
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a corneal scar from an injury or condition that happened 7 to 30 days ago.
- The scar is in the central or near-central part of your cornea and is between 2 and 5 millimeters wide.
- The scar affects your vision and you can notice it.
- You do not have a slow-healing eye or a persistent defect.
- You are willing and able to follow the study's instructions and schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new eye drop called CSB-001 for people with limbal stem cell deficiency (LSCD), a condition that damages the cornea. The goal is to see if the drops can help improve the health of the cornea and reduce inflammation.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
This trial tests whether a tiny “micro-coring” device can improve the look of scars. It enrolls adults with certain skin types who have not recently treated the scar and who can safely use numbing medicine used in the procedure.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This Phase 1 study tests how safe and tolerable an investigational treatment (EO2002) is in adults having cataract surgery. It also looks at whether the treatment can be given without causing harmful effects in people with reduced cornea cell counts.
Hear when a new Corneal Scar trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.